Skip to Content


In the US, KEYTRUDA (pembrolizumab systemic) is a member of the drug class Anti-PD-1 monoclonal antibodies and is used to treat Cervical Cancer, Colorectal Cancer, Gastric Cancer, Head and Neck Cancer, Hodgkin's Lymphoma, Melanoma, Melanoma - Metastatic, Non-Small Cell Lung Cancer, Primary Mediastinal Large B-cell Lymphoma, Solid Tumors and Urothelial Carcinoma.

US matches:

UK matches:

Ingredient matches for KEYTRUDA


Pembrolizumab is reported as an ingredient of KEYTRUDA in the following countries:

  • Canada
  • France
  • Germany
  • Slovakia
  • Slovenia
  • Switzerland
  • United Kingdom
  • United States

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.